Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2020 | ALL patients & allo-HSCT

Josep-Maria Ribera • 25 Aug 2020
SOHO 2020
Acute Lymphoblastic Leukemia Leukemia

Josep M. Ribera, MD, PhD, Germans Trias i Pujol University Hospital, Barcelona, Spain, discusses his talk in Society of Hematologic Oncology (SOHO) 2020 on which acute lymphoblastic leukemia (ALL) patients should receive an allogeneic hematopoietic stem cell transplant (allo-HSCT) in first complete remission. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Josep-Maria Ribera

1:25
BURKIMAB14: dose reduction of chemotherapy in young adults with Burkitt lymphoma
Josep-Maria Ribera • 9 Jun 2023
0:55
PhALLCON: Phase III study of ponatinib vs imatinib in newly diagnosed Ph+ ALL
Josep-Maria Ribera • 9 Jun 2023
1:02
Incorporating immunotherapy into the first-line treatment of ALL
Josep-Maria Ribera • 9 Jun 2023
1:31
PETHEMA LAL19: continuation therapy or allogeneic transplantation according to MRD & genetics in ALL
Josep-Maria Ribera • 8 Oct 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals